Sacubitril/valsartan for chronic heart failure: its future potential

Chaplin, Steve

doi:10.1002/psb.1514

Cited by 2 publications

(1 citation statement)

References 13 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 9 , 10 , 11 Sacubitril/valsartan (Entresto®)—a drug that inhibits degradation of natriuretic peptides and increases BNP 12 —has been shown to substantially lower mortality in patients with heart failure with reduced ejection fraction. 13 , 14 The addition of sacubitril/valsartan to standard therapy in heart failure led to decreased cardiac sympathetic activity and increase survival. 15 While sacubitril/valsartan is approved for the treatment of heart failure, 16 its potential for the treatment of TTS has been explored neither in experimental nor in clinical settings.…”

Section: Introductionmentioning

confidence: 99%

Sacubitril/valsartan decreases mortality in the rat model of the isoprenaline‐induced takotsubo‐like syndrome

et al. 2021

View full text Add to dashboard Cite

Aims Takotsubo syndrome (TTS) is an acute potentially reversible cardiac syndrome characterized by variable regional myocardial akinesia that cannot be attributed to a culprit coronary artery occlusion. TTS is an important differential diagnosis of acute heart failure where brain natriuretic peptides are elevated. Sacubitril/valsartan is a novel and effective pharmacological agent for the treatment of patients with heart failure. Our aim was to explore whether treatment with sacubitril/valsartan could prevent isoprenaline-induced takotsubo-like phenotype in rats. Methods and results A total number of 186 Sprague-Dawley male rats were randomized to receive pretreatment with water (CONTROL, n = 62), valsartan (VAL, n = 62), or sacubitril/valsartan (SAC/VAL, n = 62) before receiving isoprenaline for induction of TTS. We recorded heart rate and blood pressure invasively. Cardiac morphology and function were evaluated by high-resolution echocardiography 90 min after the administration of isoprenaline. We documented the survival rate at the time of echocardiography. Compared with the CONTROL group, the SAC/VAL group had less pronounced TTS-like cardiac dysfunction and lower mortality rate, while the VAL group did not differ. Heart rate and blood pressure were not significantly different between the groups. Analysis of cardiac lipids was performed with mass spectrometry. The VAL and SAC/VAL groups had significantly higher levels of lysophosphatidylcholine (LPC), in particular LPC 18:1 and LPC 16:0. Conclusions Pretreatment with sacubitril/valsartan but not with valsartan reduces mortality and attenuates isoprenalineinduced apical akinesia in the TTS-like model in rats. Sacubitril/valsartan could be a potential treatment option in patients with TTS in humans.

show abstract

Section: Introductionmentioning

confidence: 99%

Sacubitril/valsartan decreases mortality in the rat model of the isoprenaline‐induced takotsubo‐like syndrome

et al. 2021

View full text Add to dashboard Cite

show abstract

Sacubitril valsartan for chronic heart failure: a practical context

Brennan

2018

British Journal of Cardiac Nursing

View full text Add to dashboard Cite

Heart failure is a condition with high morbidity and mortality. Pharmacological treatment has greatly contributed to improved outcomes and experiences of people living with heart failure. A new agent, sacubitril valsartan, has been approved for patients with heart failure and reduced ejection fraction. This article discusses the evidence base, mechanism of action, clinical indications and practical considerations for the use of sacubitril valsartan in practice.

show abstract

Sacubitril/valsartan for chronic heart failure: its future potential

Cited by 2 publications

References 13 publications

Sacubitril/valsartan decreases mortality in the rat model of the isoprenaline‐induced takotsubo‐like syndrome

Sacubitril/valsartan decreases mortality in the rat model of the isoprenaline‐induced takotsubo‐like syndrome

Sacubitril valsartan for chronic heart failure: a practical context

Contact Info

Product

Resources

About